Top

Published in:

01-10-2003 | Original Article

The effects of αGalCer-induced TCRVα24 Vβ11⁺ natural killer T cells on NK cell cytotoxicity in umbilical cord blood

Authors: Yoko Ueda, Masao Hagihara, Balgansuren Gansuvd, Ying Yu, Aya Masui, Ayako Okamoto, Ayako Higuchi, Kei Tazume, Syunichi Kato, Tomomitsu Hotta

Published in: Cancer Immunology, Immunotherapy | Issue 10/2003

Abstract

Purpose

The first objective of this study was to investigate in vitro effects of α-galactosylceramide (αGalCer) on the proliferation of umbilical cord blood (UCB) natural killer T (NKT) cells and enhancement of their cytotoxicity. The second one is to examine whether purified NKT cells could affect the cytotoxicity of UCB-NK cells either in the presence or absence of dendritic cells (DCs).

Methods

Mononuclear cells (MNCs) from UCB were cultured for 2 weeks in the presence of IL-2 (100 U/ml), with or without αGalCer. The effect of neutralizing monoclonal antibodies (MoAb) against TCRVα24 and CD1d was also examined. TCRVα24 Vβ11 double positive NKT cells were purified by FACS sorter and then cocultured with syngeneic isolated UCB⁻CD56⁺NK cells in either the presence or absence of DCs. The cytotoxicity against various malignant cell targets and cytokine production was determined.

Results

The addition of αGalCer induced human NKT cells to proliferate in UCB-MNCs to a greater extent than in adult PB-MNCs. However, it suppressed the cytotoxic activity against malignant cell targets. Anti-TCRVα24 and CD1d MoAb recovered the cytotoxicity by inhibiting the proliferation of UCB-NKT cells. NKT cells cocultured with auto-DCs significantly increased NK cell cytotoxicity against K562, and Raji cells and produced IFN-γ at much higher levels than UCB-NKT cells alone.

Conclusion

In UCB samples, αGalCer–pulsed DCs and NKT cells acted together to enhance NK cytotoxicity in vitro.

Nakagawa R, Motoki K, Nakamura H, Ueno H, Iijima R, Yamauchi A, Tsuyuki S, Inamoto T, Koezuka Y (1998) Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production. Oncol Res 10:561PubMed

Nakagawa R, Motoki, Ueno H., Iijima R, Nakamura H, Kobayashi E, Shimosaka A, Koezuka Y (1998) Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res 58:1202PubMed

Kawano T, Cui J, Koezuka Y, Toura I., Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M (1997) CD1d-restricted and TCR-mediated activation of Valpha14 NKT cells by glycosylceramides. Science 278:1626PubMed

Porcelli SA, Yockey CE, Brenner MB, Balk SP (1993) Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4–8-alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med 178:1PubMed

Brooks EG., Balk SP, Aupeix K, Colonna M, Strominger JL, Groh-Spies V (1993) Human T-cell receptor (TCR) alpha/beta + CD4^-CD8^- T cells express oligoclonal TCRs, share junctional motifs across TCR V beta-gene families, and phenotypically resemble memory T cells. Proc Natl Acad Sci USA 90:11787PubMed

Kawano T, Tanaka Y, Shimizu E, Kaneko Y, Kamata N, Sato H, Osada H, Sekiya S, Nakayama T., Taniguchi M (1999) A novel recognition motif of human NKT antigen receptor for a glycolipid ligand. Int Immunol 11:881CrossRefPubMed

Kawano T, Nakayama T, Kamada N, Kaneko Y, Harada M, Ogura N, Akutsu Y, Motohashi S. Iizasa T, Endo H, Fujisawa T, Shinkai H, Taniguchi M (1999) Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 59:5102PubMed

Nieda M, Nicol A, Koezuka Y, Kikuchi A, Takahashi T, Nakamura H, Furukawa H, Yabe T, Ishikawa Y, Tadokoro K, Juji T (1999) Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24TCR-mediated manner. Hum Immunol 60:10CrossRefPubMed

Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, Durrant S, Juji T (2000) Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: an important immune regulatory function. Exp Hematol 28:276PubMed

10.

Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, Durrant S, Juji T (2000) Human invariant Valpha24⁺ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology 99:229CrossRefPubMed

11.

Takahashi T, Nieda M, Koezuka Y, Nicol A, Porcelli SA, Ishikawa Y, Tadokoro K, Hirai H, Juji T (2000) Analysis of human V alpha 24⁺ CD4⁺ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 164:4458PubMed

12.

Hagihara M, Gansuvd B, Ueda Y, Tsuchiya T, Masui A, Tazume K, Inoue H., Kato S, Hotta T. (2002) Killing activity of human umbilical cord blood derived TCRValpha 24⁺ NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells. Cancer Immunol Immunother 51:1CrossRefPubMed

13.

Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T (1999) The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 189:1121PubMed

14.

Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, Kondo E, Harada M, Koseki H, Nakayama T, Tanaka Y, Taniguchi M (1998) Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 95:5690CrossRefPubMed

15.

Eberl G., MacDonald HR (2000) Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 30:985CrossRefPubMed

16.

Ishihara S, Nieda M, Kitayama J, Osada T, Yabe T, Kikuchi A, Koezuka Y, Porcelli SA, Tadokoro K, Nagawa H, Juji T (2000) Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3⁻CD56⁺ NK cells in vitro. J Immunol 165:1659PubMed

17.

Gluckman E, Rocha V, Chastang C (1999) Cord Blood stem cell transplantation. Baillieres Best Pract Res Clin Haematol 12:279CrossRefPubMed

18.

Sanz MA, Sanz GF (2002) Unrelated donor umbilical cord blood transplantation in adults. Leukemia 16:1984CrossRef

19.

El Marsafy S, Dosquet C, Coudert M-C, Bensussan A, Carosella E, Gluckman E (2001) Study of cord blood natural killer cells suppressor activity. Eur J Haematol 66:215CrossRefPubMed

20.

Nomura A, Takeda H, Jin CH, Tanaka T, Ohga S, Hara T (2001) Functional analyses of cord blood killer cells and T cells: a distinctive interleukin-18 response. Exp Hematol 29:1169CrossRefPubMed

21.

Webb BJ, Bochan MR, Montel A, Padilla LM, Brahmi Z (1994) The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum. Cell Immunol 159:246PubMed

22.

Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245PubMed

23.

Poggi A, Carosio R, Spaggiari GM, Fortis C, Tambussi G, Dell'Antonio G, Dal Cin E, Rubartelli A, Zocchi MR (2002) NK cell activation by dendritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 Tat C-terminal domain. J Immunol 168:95PubMed

24.

Yu Y, Hagihara M, Ando K, Gansuvd B, Matsuzawa H, Tsuchiya T, Ueda Y, Inoue H, Hotta T, Kato S (2001) Enhancement of human cord blood CD34⁺ cell-derived NK cell cytotoxicity by dendritic cells. J Immunol 166:1590PubMed

25.

Exley M, Garcia J, Wilson SB, Spada F, Gerdes D, Tahir SM, Patton KT, Blumberg RS, Porcelli S, Chott A, Balk SP (2000) CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology 100:37CrossRefPubMed

26.

Hameg A, Apostolou I, Leite-de-Moraes M, Gombert J-M, Garcia C, Kowzuka Y, Bach J-F, Herbelin A (2000) A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the α-galactosylceramide antigen. J Immunol 165:4917PubMed

27.

MacDonald KP, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DN (2002) Characterization of human blood dendritic cell subsets. Blood 100:4512CrossRefPubMed

28.

Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R, Gnant M (2003) Dendritic cell-based vaccination in solid cancer. J Clin Oncol 21:135CrossRefPubMed

29.

Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52PubMed

30.

Okai M, Nieda M, Tazbirkova A, Horley D, Kikuchi A, Durrant S, Takahashi T,. Boyd A, Abraham R, Yagita H, Juji T, Nicol A (2002) Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells. Vox Sang 83:250CrossRefPubMed

31.

van der Vliet HJJ, Nishi N, de Gruiji TD, von Blomenberg BME, van den Eertwegh AJM, Pinedo HM, Giaccone G., Scheper RJ (2000) Human natural killer T cells acquire a memory-activated phenotype before birth. Blood 95:2440PubMed

32.

Gumperz JE, Roy C, Makowska A, Lum D, Sugita M, Podrebarac T, Koezuka Y, Porcelli SA, Cardell S, Brenner MB, Behar SM. (2000) Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12:211PubMed

33.

Kadowaki N, Antonenko S, Ho S, Rissoan MC, Soumelis V, Porcelli SA, Lanier LL, Liu YJ (2001) Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. J Exp Med 193:1221PubMed

34.

Singh N, Hong S, Scherer DC, Serizawa I, Burdin N, Kronenberg M, Koezuka Y, Van Kaer L (1999) Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol 163:2373PubMed

35.

Fujii S, Shimizu K, Kronenberg M, Steinman RM (2002) Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3:867CrossRefPubMed

36.

Mosca PJ, Hobeika AC, Clay TM, Nair SK, Thomas EK, Morse MA, Lyerly HK (2000) A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-γ treatment. Blood 96:3499PubMed

37.

Tomura M, Yu WG., Ahn HJ, Yamashita M, Yang YF, Ono S, Hamaoka T, Kawano T, Taniguchi M, Koezuka Y, Fujiwara H (1999) A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol 163:93PubMed

38.

Nakagawa R, Nagafune I., Tazunoki Y, Ehara H, Tomura H, Iijima R, Motoki K, Kamishohara M, Seki S (2001) Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α-galactosylceramide in mice. J Immunol 166:6578PubMed

39.

Seino K, Fukao K, Muramoto K, Yanagisawa K, Takad Y, Kakuta S, Iwakura Y, Van Kaer L, Takeda K, Nakayama T, Taniguchi M, Bashuda H., Yagita H, Okumura K (2001) Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci USA 98:2577PubMed

40.

Ito K, Karasawa M, Kawano T, Akasaka T, Koseki H, Akutsu Y, Kondo E, Sekiya S, Sekikawa K, Harada M, Yamashita M, Nakayama T, Taniguchi M (2000) Involvement of decidual Valpha14 NKT cells in abortion. Proc Natl Acad Sci USA 97:740CrossRefPubMed

41.

Hammond K, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, Baxter AG. (1998) alpha/beta-T cell receptor (TCR)+CD4⁻CD8⁻ (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 187:1047PubMed

42.

Baxter AG., Kinder SJ, Hammond KJ, Scollay R, Godfrey DI. (1997) Association between alphabetaTCR⁺CD4^-CD8⁻ T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 46:572PubMed

Title: The effects of αGalCer-induced TCRVα24 Vβ11+ natural killer T cells on NK cell cytotoxicity in umbilical cord blood
Authors: Yoko Ueda
Masao Hagihara
Balgansuren Gansuvd
Ying Yu
Aya Masui
Ayako Okamoto
Ayako Higuchi
Kei Tazume
Syunichi Kato
Tomomitsu Hotta
Publication date: 01-10-2003
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 10/2003
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-003-0398-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2003

Tumor immunotherapy by converting tumor cells to MHC class II–positive, Ii protein–negative phenotype

Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients

Synopsis of the 5th annual Cancer Vaccines and Immunotherapy Colloquium at Walker's Cay

Generation of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells

Optimizing dendritic cell–based anticancer immunotherapy: maturation state does have clinical impact

Rapid turnover of the CD8+CD28- T-cell subset of effector cells in the circulation of patients with head and neck cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer